Issues lobbied + lobbyists
PHA — Pharmacy
Drug pricing issues Prescription Drug User Fee Act reauthorization Issues related to prescription drug value Issues related to the 340B Drug Discount Program
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
MAN — Manufacturing
Issues related to pharmaceutical supply chains Issues related to reporting on location of origin of pharmaceutical products Issues related to drug shortages Issues related to pharmaceutical manufacturing
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
IMM — Immigration
Issues relating to limits and restrictions on the immigration of high skilled workers Issues relating to the immigration of medical researchers
Government entities lobbied: Homeland Security, Dept of (DHS); Labor, Dept of (DOL)
BUD — Budget/Appropriations
Issues related to FDA and HHS program funding for the FY25 Labor, HHS, Education and Related Agencies, and FY25 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills Strategic National Stockpile (SNS) Funding and Oversight Funding for FDA e-labeling rule implementation Patient access to Part B medicineS Issues related to 340B program oversight Support for increased investments to address antimicrobial resistance Deficit reduction, reconciliation
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
CPT — Copyright/Patent/Trademark
Intellectual property and process patent issues Patent litigation reforms PTAB and IPR processes Section 101 Reform Domestic and international compulsory licensing issues March-in Rights
Government entities lobbied: Patent & Trademark Office (PTO); U.S. Trade Representative (USTR)
HCR — Health Issues
Issues related to the 340B Drug Discount Program Issues relating to drug pricing Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. Issues related to healthcare legislation Patient access to Part B medicines Issues related to health equity, diversity, and inclusion in clinical trials Issues related to advanced development and procurement of medical countermeasures (MCMs) Issues related to patient assistance and access Issues relating to privacy and securing the data of and personal information of consumers Issues relating to medical research data Issues relating to screening and diagnostics Issues related to public health preparedness and response Issues related to awareness about diabetic eye diseases in minority populations Issues related to public health preparedness. Issues related to access to drugs for minority communities Issues related to healthcare education and screening
Government entities lobbied: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE
MMM — Medicare/Medicaid
Issues related to Medicare and Medicaid coverage and reimbursement Issues related to the 340B Drug Discount Program Issues related to drug pricing Medicare reimbursement for biosimilars Issues related to CMMI
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
TAX — Taxation/Internal Revenue Code
Issues related to R&D tax deductions and expense amortization Issues related to international taxation, including foreign-derived intangible income and interest deductions Issues related to supply chain incentives
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE; Treasury, Dept of
TRD — Trade (domestic/foreign)
Issues relating to trade policy and negotiations impacting the biopharmaceutical industry including the TRIPS IP Waiver Issues related to compulsory licensing of foreign patents Issues related to WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)
Government entities lobbied: HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO); SENATE; U.S. Trade Representative (USTR)
MED — Medical/Disease Research/Clinical Labs
Issues related to public health protection including influenza development and preparedness Issues related to antimicrobial and antiviral research and product development Issues related to research and product development Issues related to drug development including PDUFA
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE